Page results
-
UCLH vision, values and strategy
-
Information about clinic-based after-care following treatment for childhood or teenage cancer at UCLH.
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
Information about the Integrative Talking Therapies service at the Royal London Hospital for Integrated Medicine.
-
The Neuroimmunology and CSF Laboratory at the Institute of Neurology, UCLH is a UKAS accredited medical laboratory No. 8045.
-
Bones marrow harvest patient information page.
-
This service provides a tertiary level, second opinion service, specialising in the diagnostic assessment and treatment of complex speech sound disorders. The team has particular expertise in Childhood Apraxia of Speech (CAS).
-
Advice on socialising and managing friendships for young people living with fatigue conditions.
-
This page provides information about ERCP (Endoscopic Retrograde Cholangiopancreatography) procedure.
-
Health and wellbeing information for people affected by cancer.
File results
-
FOI2017307 Televisions for patients
-
FOI/2023/0352 - Security training/ Data breaches/ Security budgets/ Digital cyber security services
-
FOI/2023/0360 - Minutes of Board of Director meetings and Declarations of Interests (DoI) statements 2008-2023
-
FOI/2023/0192 - Non emergency patient transport - NEPTS and taxi procurement
-
FOI/2023/0201 - Gas and air suspension in maternity unit
-
FOI/2023/0199 - Patients diagnosed with Cauda Equina Syndrome
-
FOI/2023/0195 - Patient level costing system and integrated data platform
-
FOI/2023/0206 - Service and maintenance contracts for digital/ smart buildings platform, fire alarms, security/ CCTV
-
FOI/2023/0187 - Treatment for urothelial and colorectal cancer
-
FOI/2023/0182 - Data privacy compliance tools